Writing Group Disclosures

Writing Group Member	Employment	Research Grant	Other Research Support	Speakers Bureau/Honoraria	Expert Witness	Ownership Interest	Consultant/Advisory Board	Other
Michael W. Rich	Washington University School of Medicine	NIA*; NHLBI*	None	None	None	None	None	None
Deborah A. Chyun	New York University	None	None	None	None	None	Qatar National Research Fund*	None
Karen P. Alexander	Duke University Medical Center	None	None	None	None	None	None	None
Daniel E. Forman	University of Pittsburgh Medical Center	None	None	None	None	None	None	None
Dalane W. Kitzman	Wake Forest University School of Medicine	NIH†; Novartis†	None	None	None	Gilead, Inc. Stock Ownership†; Relypsa Inc.*	GSK*; Relypsa*; Regeneron*; AbbVie†; DC Devices*; Abbott Pharmaceuticals*; Actavis*; ICON†	None
Mathew S. Maurer	Columbia College of Physicians and Surgeons	None	None	None	None	None	None	None
James B. McClurken	Doylestown Health Heart Institute	Silver AMI*	None	None	None	None	None	None
Barbara M. Resnick	University of Maryland	None	None	None	None	None	None	None
Win K. Shen	Mayo Clinic	None	None	None	None	None	None	None
Adam H. Skolnick	NYU School of Medicine	None	None	None	None	None	None	None
David L. Tirschwell	Harborview Medical Center	St. Jude Medical†; Bayer*	None	None	None	None	None	None

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10, 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10, 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

^*Modest.

^†Significant.